Sotorasib Shows Modest Activity in KRAS G12C Pancreatic Cancer

This trial provides the first prospective efficacy and safety data for a KRAS G12C inhibitor in a rare molecular subset of previously treated pancreatic cancer, informing off-label and future use decisions.

📅 Journal publication: Jan 5, 2023 (online Dec 21, 2022) · Last updated: Aug 26, 2026

sotorasibKRAS G12C inhibitorpancreatic cancerpancreatic ductal adenocarcinomatargeted therapyCodeBreaK 100phase 1-2 trialmolecular profilingprecision oncology Oncology Pharmacy

Background Information

Sotorasib offers hope for KRAS p.G12C-mutated pancreatic cancer.

KRAS p.G12C mutation is present in a small percentage of pancreatic cancers, highlighting the need for targeted treatments like sotorasib. In the trial, 21% of patients had a confirmed objective response to sotorasib, with a median progression-free survival of 4.0 months and overall survival of 6.9 months. Sotorasib demonstrates potential as a targeted therapy for advanced pancreatic cancer with KRAS p.G12C mutation, offering a new option for previously treated patients. Sotorasib shows promise with manageable safety in KRAS p.G12C-mutated advanced pancreatic cancer.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, Schuler M, Burns TF, Coveler AL, Falchook GS, Vincent M, Sunakawa Y, Dahan L, Bajor D, Rha SY, Lemech C, Juric D, Rehn M, Ngarmchamnanrith G, Jafarinasabian P, Tran Q, Hong DS

Citation: Strickler JH, Satake H, George TJ, et al. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. The New England journal of medicine. 2023;388(1):33-43. doi:10.1056/NEJMoa2208470

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →